Table 3.

Clinical effectiveness of LDM therapy.

	Pre-LDMs	Post-LDMs	p value
TNS, mean ± SD	8.67 ± 1.03	2.83 ± 1.33	<0.01*
Nasal obstruction, n (%)	6/6 (100%)	4/6 (67%)	N/A
Rhinorrhea/PND, n (%)	5/6 (83%)	3/6 (50%)	1.00
Facial pain, n (%)	0/6 (0%)	0/6 (0%)	N/A
Loss of smell, n (%)	3/6 (50%)	0/6 (%)	N/A
Cough, n (%)	6/6 (100%)	2/6 (33%)	N/A
Physician assessment nasal D/C			N/A
No D/C	1/6 (17%)	5/6 (83%)
Thin watery D/C	1/6 (17%)	1/6 (17%)
Thick mucoid D/C	2/6 (33%)	0/6 (0%)
Purulent D/C	0/6	0/6 (0%)

TNS: total nasal symptom, LDMs = low-dose macrolides, D/C = discharge, PND = postnasal drip; N/A: not applicable (McNemar’s test cannot be done when one of the cell frequencies is 0.)

^*p < 0.05.